RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Wayne W. Harding to Aporphines

This is a "connection" page, showing publications Wayne W. Harding has written about Aporphines.
Connection Strength

6.913
  1. Namballa HK, Madapa S, Sigalapalli DK, Harding WW. Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT2A/2CR Antagonist. J Nat Prod. 2022 09 23; 85(9):2149-2158.
    View in: PubMed
    Score: 0.839
  2. Karki A, Namballa HK, Alberts I, Harding WW. Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT7AR ligands. Bioorg Med Chem. 2020 08 01; 28(15):115578.
    View in: PubMed
    Score: 0.720
  3. Karki A, Juarez R, Namballa HK, Alberts I, Harding WW. Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity. Bioorg Med Chem Lett. 2020 04 15; 30(8):127053.
    View in: PubMed
    Score: 0.705
  4. Ponnala S, Kapadia N, Madapa S, Alberts IL, Harding WW. Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor. Bioorg Med Chem Lett. 2015 Nov 15; 25(22):5102-6.
    View in: PubMed
    Score: 0.521
  5. Kapadia N, Harding WW. C4 phenyl aporphines with selective h5-HT(2B) receptor affinity. Bioorg Med Chem Lett. 2015 Sep 01; 25(17):3451-4.
    View in: PubMed
    Score: 0.512
  6. Madapa S, Harding WW. Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors. J Nat Prod. 2015 Apr 24; 78(4):722-9.
    View in: PubMed
    Score: 0.499
  7. Ponnala S, Kapadia N, Navarro HA, Harding WW. Aporphinoid antagonists of 5-HT2A receptors: further evaluation of ring A substituents and the size of ring C. Chem Biol Drug Des. 2014 Nov; 84(5):558-66.
    View in: PubMed
    Score: 0.474
  8. Ponnala S, Gonzales J, Kapadia N, Navarro HA, Harding WW. Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity. Bioorg Med Chem Lett. 2014 Apr 01; 24(7):1664-7.
    View in: PubMed
    Score: 0.466
  9. Chaudhary S, Ponnala S, Legendre O, Gonzales JA, Navarro HA, Harding WW. New aporphinoid 5-HT2A and a1A antagonists via structural manipulations of nantenine. Bioorg Med Chem. 2011 Oct 01; 19(19):5861-8.
    View in: PubMed
    Score: 0.391
  10. Ponnala S, Chaudhary S, Gonz?lez-Sarrias A, Seeram NP, Harding WW. Cytotoxicity of aporphines in human colon cancer cell lines HCT-116 and Caco-2: an SAR study. Bioorg Med Chem Lett. 2011 Aug 01; 21(15):4462-4.
    View in: PubMed
    Score: 0.386
  11. Pecic S, McAnuff MA, Harding WW. Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. J Enzyme Inhib Med Chem. 2011 Feb; 26(1):46-55.
    View in: PubMed
    Score: 0.361
  12. Pecic S, Makkar P, Chaudhary S, Reddy BV, Navarro HA, Harding WW. Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies. Bioorg Med Chem. 2010 Aug 01; 18(15):5562-75.
    View in: PubMed
    Score: 0.361
  13. Legendre O, Pecic S, Chaudhary S, Zimmerman SM, Fantegrossi WE, Harding WW. Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15; 20(2):628-31.
    View in: PubMed
    Score: 0.347
  14. Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW. (+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners. Bioorg Med Chem Lett. 2009 May 01; 19(9):2530-2.
    View in: PubMed
    Score: 0.331
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support